Business context and reporting period
Issuer mismatch: The supplied filing is Tiger X Medical, Inc.’s Form 10-K for the fiscal year ended December 31, 2014—not a BioCardia, Inc. filing. It reports annual results; it does not provide separate fourth-quarter financial results.
Tiger X had sold substantially all of its former orthopedic-device business assets in 2011. Its continuing activity was collecting royalties from Arthrex, promoting former products, seeking a partner or buyer for remaining intellectual property, and evaluating uses for its cash. It reported five remaining issued patents related to intervertebral stabilizers.
Financial performance and position
Amounts below are in U.S. dollars; financial statement amounts are in thousands unless noted.
| Metric | FY2014 | FY2013 |
|---|---|---|
| Royalty income | $427,000 | $268,000 |
| General and administrative expenses | $196,000 | $259,000 |
| Operating income | $231,000 | $9,000 |
| Interest income | $3,000 | $10,000 |
| Net income | $234,000 | $19,000 |
| Operating cash flow | $214,000 | $27,000 |
| Cash at year-end | $13.509 million | $13.295 million |
| Total assets | $13.545 million | $13.328 million |
| Total liabilities | $1,000 | $18,000 |
| Debt | None reported | None reported |
Royalty income rose about 59% year over year, which management attributed to higher Arthrex sales. G&A declined about 24%, primarily because 2013 included higher business taxes and professional fees. Operating margin was approximately 54% in 2014 versus 3% in 2013; net margin was approximately 55% versus 7%, respectively, based on reported income and royalty income. No income-tax provision was recorded in either year. The income statement displays basic and diluted earnings per share as “$ -”; it does not provide a clear per-share value.
The company reported no investing or financing cash flows in either year and no off-balance-sheet financing arrangements or contractual obligations. Working capital was approximately $13.544 million at year-end 2014, based on reported current assets and liabilities. Management said cash was adequate for needs over the next 12 months and beyond.
Material changes, outlook and risks
- Under its Arthrex agreement, Tiger X receives royalties equal to 5% of net sales of acquired Reconstructive Division products, paid quarterly for up to 20 years after closing. Royalties received were $427,000 in 2014 and $268,000 in 2013.
- Management expected royalties to remain the primary revenue source until a partner or buyer for remaining intellectual property, or an investment opportunity, is found. It expected G&A expenses to remain near the 2014 level. No specific revenue or earnings guidance was provided.
- Material risks include dependence on Arthrex royalty receipts and the ability to verify or enforce them; possible royalty offsets tied to third-party intellectual-property claims; limited operations and personnel; and uncertainty about future investments, acquisitions, or financing.
- Product-liability exposure from previously sold devices remains, with tail insurance currently maintained; the filing warns that coverage may be inadequate and that the company may be self-insured after the policy term. The filing says no pending or threatened legal proceedings were believed to have a material effect.
- Cash concentration is notable: bank balances exceeded FDIC insurance limits by $13.274 million at December 31, 2014. The company reported no prior losses from this concentration.
- The company reported that management considered disclosure controls and internal control over financial reporting effective at year-end. The auditor audited the financial statements and issued an unqualified opinion, but did not attest to internal control effectiveness.
Important facts for investors to verify
- Confirm the intended issuer and filing: the source document identifies Tiger X Medical, Inc., not BioCardia, Inc.
- Review Arthrex sales, royalty calculations, payment history, agreement terms, and any potential offsets or disputes.
- Assess the company’s remaining intellectual property, prospects for a partner or buyer, and any contemplated use of its cash.
- Verify cash custody and uninsured deposit exposure, along with the company’s assumptions behind its liquidity outlook.
- Consider the thinly traded OTC shares, reported ownership concentration, and potential dilution from authorized shares and outstanding options.